Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2016 ENFERMEDAD GRUPO REGISTRY PROYECTOS ENTRAR
 
 
  
Experimental Rx -
--->Novedades
[-]El proyecto
--->Sponsor
--->[+]Comité Ejecutivo
--->[+]Writing Committee Strategic ...
--->[+]Comité Científico y Bioético
--->Coordinador central
--->Coordinadores locales
--->Fellowship Programme
--->[+]Constitución
--->[+]Elecciones
--->[-]Miembros
--->Solicitud
[-]Centros
--->[+]Austria
--->[+]Bélgica
--->[+]República Checa
--->[-]Dinamarca
--->[+]Coordination
--->HD Associations
--->Aarhus
--->Copenhagen
--->Odense
--->[+]Finlandia
--->[+]Francia
--->[+]Alemania
--->[+]Ireland
--->[+]Italia
--->[+]Países Bajos
--->[+]Noruega
--->[+]Polonia
--->[+]Portugal
--->[+]Rusia
--->[+]España
--->[+]Suecia
--->[+]Suiza
--->[-]Reino Unido
--->Coordinación
--->Asociaciones de Huntingto...
--->Links
--->[+]UKHDN
--->Standard of Care
--->Aberdeen
--->[+]Ayr
--->Belfast
--->Birmingham
--->[+]Blandford Forum
--->Bristol
--->Cambridge
--->Cardiff
--->Dundee
--->Edinburgh
--->Exeter
--->Fife
--->Forth Valley
--->Glasgow
--->Gloucester
--->Hull
--->Inverness
--->Launceston
--->Leeds
--->Leicester
--->Liverpool
--->Londres - Guy's Hospital
--->Londres - Hammersmith
--->Londres - NHNN
--->Londres - Royal Hospital
--->Londres St. George´s
--->Manchester
--->Newcastle-Upon-Tyne
--->[+]Northampton
--->Nottingham
--->Oxford
--->[+]Plymouth
--->Poole
--->Preston
--->Reading
--->[+]Sheffield
--->Southampton
--->Stoke-on-Trent
--->Swindon
--->Wrexham
--->[-]Fuera de Europa
--->[+]Seoul
--->[+]Singapore
--->Sydney
[-]Grupos de trabajo
--->[+]EH avanzada
--->[+]Fenotipo conductual
--->[+]Modificadores Biológicos
--->[+]Biomarcadores
--->[+]Banco de tejidos y cerebros...
--->[-]Fenotipo cognitivo
--->[+]Acontecimientos
--->[-]Reuniones
--->Reunión 2005/03
--->Reunión 2008/09
--->Reunión 2009
--->Meeting 2012
--->[+]Modificadores ambientales
--->[+]Evaluación Funcional
--->[-]Test y Consejo genético
--->[+]Acontecimientos
--->[+]Reuniones
--->[-]Genes Modificadores
--->[+]Acontecimientos
--->[-]Reuniones
--->Reunión 2005/09
--->Reunión 2006/04
--->Reunión 2008/09
--->Reunión 2009/06
--->Meeting 2012/13
--->[-]Economia de Salud
--->Acontecimientos
--->[+]Reuniones
--->[-]Pruebas de imagen
--->[+]Acontecimientos
--->[-]Reuniones
--->Reunión 2007
--->Reunión 2008/09
--->Reunión 2009
--->Meeting 2012
--->Meeting 2014
--->Meeting 2016
--->[+]Huntington Juvenil
--->[+]Fenotipo motor
--->[+]Tratamiento Neuroprotector...
--->[+]Fisioterapia
--->[-]Calidad de vida
--->[+]Acontecimientos
--->[-]Reuniones
--->Reunión 2005/03
--->Reunión 2005/09
--->Reunión 2006/07
--->Reunión 2006/12
--->Reunión 2007/09
--->Reunión 2008/08
--->Reunión 2008/09
--->Reunión 2009/11
--->Meeting 2010/05
--->Meeting 2016/09
--->Meeting 2017/07
--->[+]Cuidados del paciente
--->[-]Tratamiento quirúrgico
--->Acontecimientos
--->[+]Reuniones
--->[+]Tratamiento Sintomático
--->[+]Jóvenes
[-]Eventos
--->[+]EHDN 2016
--->EHDN 2014
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[-]Documents
--->Handouts
--->Presentations
--->[-]Posters
--->Pathogenic mechanisms
--->Animal models
--->Choreatic disorders - no...
--->Genetic modifiers
--->Wet Biomarkers
--->Imaging
--->Clin characteristics
--->Clin char-motor
--->Clin char-cognitive
--->Clin char - behaviour
--->Clin char-other
--->Clinical studies
--->Genetic testing
--->Clinical care
--->Experimental Rx
--->Clinical Rx
--->Non-scientific
--->Contacts
--->Feedback & Evaluation
--->[+]EHDN 2010
--->[+]EHDN 2008
--->[+]EHDN 2007
--->[+]EHDN 2006
--->[+]EHDN 2005
--->[+]EHDN 2004
[+]Comunicación
--->Ofertas de trabajo
fechadescripcióntamañoautor documento 
04.08.26In vivo efficacy of (CUG)n oligonucleotides to treat HD32 kBanonymousapplication/mswordp02-in-vivo-efficacy-oligonucleotides 
04.08.26Antisense oligonucleotide mediated transcript reduction and modulation – the European approach to develop a therapy for Huntington Disease32 kBanonymousapplication/mswordp01-antisense-oligonucleotide-transcript 
04.08.26Reducing toxic n-terminal Huntingtin fragments in HD using exon skipping32 kBanonymousapplication/mswordp03-exon-skipping 
04.08.26A Huntingtin peptide inhibits polyQ-hHtt associated defects32 kBanonymousapplication/mswordp04-polyq-hhtt-associated-defects 
04.08.26Astrocytes affect neuroprotection: Glatiramer acetate in Huntington`s Disease therapy32 kBanonymousapplication/mswordp07-glatiramer-acetate 
04.08.26Olesoxime improves specific features of the HD pathology32 kBanonymousapplication/mswordp06-olesoxime 
04.08.26Analysis of Nrf2-downstream targets after fumarate treatment in dorsal root ganglia – an anti-inflammatory therapy in neurodegenerative disease?!32 kBanonymousapplication/mswordp08-analysis-of-nrf2 

Esta carpeta contiene 7 documentos.
about us | privacy statement | disclaimer | terms of use